Mark Samaan
YOU?
Author Swipe
View article: Effectiveness and safety of upadacitinib in a real-world cohort of patients with Crohn’s disease in the UK: a multicentre retrospective cohort study
Effectiveness and safety of upadacitinib in a real-world cohort of patients with Crohn’s disease in the UK: a multicentre retrospective cohort study Open
Objective Upadacitinib is the first Janus kinase inhibitor and oral advanced therapy licensed for Crohn’s disease (CD). Following NICE approval in 2023, real-world data on outcomes are limited. The effectiveness and safety of upadacitinib …
View article: Development and External Validation of an Endoscopic and Histologic Pouchitis Assessment Tool: The Atlantic Pouchitis Index
Development and External Validation of an Endoscopic and Histologic Pouchitis Assessment Tool: The Atlantic Pouchitis Index Open
Development and validation of the API advances pouchitis disease assessment. Integration of endoscopy and histopathology results in an objective, reliable, and responsive instrument to evaluate therapy effectiveness in research and clinica…
View article: The Current Sphingosine 1 Phosphate Receptor Modulators in the Management of Ulcerative Colitis
The Current Sphingosine 1 Phosphate Receptor Modulators in the Management of Ulcerative Colitis Open
Sphingosine 1 phosphate receptor (S1PR) modulators are the latest drug class to have received approval for the treatment of ulcerative colitis, and have brought a new mechanism of action to this landscape. They target immune cell trafficki…
View article: OP13 Higher neoplasia detection rate and lower number of targeted biopsies associated with virtual chromoendoscopy in IBD surveillance: a real-world, multicentre UK study
OP13 Higher neoplasia detection rate and lower number of targeted biopsies associated with virtual chromoendoscopy in IBD surveillance: a real-world, multicentre UK study Open
Background Dye chromoendoscopy (DCE) with targeted biopsies has traditionally been considered the gold standard for optimal detection of dysplasia in the context of inflammatory bowel disease (IBD) surveillance. Randomised trials have chal…
View article: P1169 Guselkumab maintenance treatment improves health-related quality of life in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR maintenance study
P1169 Guselkumab maintenance treatment improves health-related quality of life in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR maintenance study Open
Background Ulcerative colitis (UC) symptoms are associated with impaired health-related quality of life (HRQoL). The Phase 3 QUASAR maintenance study (NCT04033445) evaluated the efficacy and safety of guselkumab (GUS) in participants (pts)…
View article: P0992 Real-world experience of faecal microbiota transplant in ulcerative colitis
P0992 Real-world experience of faecal microbiota transplant in ulcerative colitis Open
Background Faecal microbiota transplant (FMT) is an effective treatment strategy for recurrent Clostridioides difficile infection (rCDI)1, but its role in ulcerative colitis (UC), another disease involving gut dysbiosis, is less certain2. …
View article: P0836 Real-world application of the Crohn’s disease clinical decision support tool (CDST) in both intravenous and subcutaneous vedolizumab
P0836 Real-world application of the Crohn’s disease clinical decision support tool (CDST) in both intravenous and subcutaneous vedolizumab Open
Background The clinical decision support tool (CDST) was developed from GEMINI II to help inform patient selection for intravenous (IV) vedolizumab (VDZ) in Crohn’s disease (CD). The tool’s applicability in the subcutaneous (SC) formulatio…
View article: P0169 Relapse of ulcerative colitis on dose reduction of tofacitinib is associated with markers of T-cell activation but not clinical features: a prospective, multicentre observational study
P0169 Relapse of ulcerative colitis on dose reduction of tofacitinib is associated with markers of T-cell activation but not clinical features: a prospective, multicentre observational study Open
Background Tofacitinib (TOF) is an effective treatment for ulcerative colitis (UC). A relationship between dose and both response and side-effect profile is recognised for JAK inhibitors. Dose reduction from 10mg bd to 5mg bd is therefore …
View article: P0960 Risankizumab induces radiological healing in treatment-refractory small bowel Crohn’s disease
P0960 Risankizumab induces radiological healing in treatment-refractory small bowel Crohn’s disease Open
Background Small bowel (SB) Crohn’s disease (CD) is a heterogenous condition, ranging from short segments of inflammation in the terminal ileum, to multifocal inflammatory, stricturing or fistulising phenotypes. Up to 80% of patients with …
View article: P0940 Patient perspectives from a real-world adalimumab biosimilar switching program
P0940 Patient perspectives from a real-world adalimumab biosimilar switching program Open
Background The patent expiry of adalimumab originator Humira in 2018 led to the availability of several biosimilars. Whilst the equivalence of biosimilars in their efficacy, safety and immunogenicity to the originator has been consistently…
View article: Baseline Data and Measurement Instruments Reported in Observational Studies in Inflammatory Bowel Disease: Results from a Systematic Review
Baseline Data and Measurement Instruments Reported in Observational Studies in Inflammatory Bowel Disease: Results from a Systematic Review Open
Background Heterogeneity in demographic and outcomes data with corresponding measurement instruments [MIs] creates barriers to data pooling and analysis. Several core outcome sets have been developed in inflammatory bowel disease [IBD] to …
View article: Crohn’s disease management: translating STRIDE-II for UK clinical practice
Crohn’s disease management: translating STRIDE-II for UK clinical practice Open
Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) characterised by endoscopic inflammation, progressive bowel damage and gastrointestinal lesions. Although treatment strategies for CD have traditionally focused on a stepwi…
View article: P1072 Upadacitinib appears effective in inducing clinical, biochemical, endoscopic and histologic improvements in previously treatment refractory Ulcerative Colitis
P1072 Upadacitinib appears effective in inducing clinical, biochemical, endoscopic and histologic improvements in previously treatment refractory Ulcerative Colitis Open
Background Upadacitinib is a novel, oral agent which acts by inhibition of JAK signaling. It has proven efficacy in large-scale, randomised trials for the treatment of UC. We report our real-world experience of upadacitinib as induction th…
View article: P870 Effectiveness and safety of adalimumab as first line biological treatment in Ulcerative Colitis
P870 Effectiveness and safety of adalimumab as first line biological treatment in Ulcerative Colitis Open
Background The increase in licensed therapies for ulcerative colitis (UC) is revolutionizing its treatment but making first line choice more challenging. Adalimumab (ADA) is inexpensive but, anecdotally, is sometimes regarded as less effec…
View article: Rationalizing polyp matching criteria in colon capsule endoscopy: an international expert consensus through RAND (modified DELPHI) process
Rationalizing polyp matching criteria in colon capsule endoscopy: an international expert consensus through RAND (modified DELPHI) process Open
Background: Colon capsule endoscopy (CCE) has gained momentum as an alternative modality for the investigation of the lower gastrointestinal tract. Of the few challenges that remain, the comparison and – eventually – matching of polyps at …
View article: P514 Beyond the First Attempt: A Multi-Centre UK Analysis of Second JAK Inhibitor Use in Ulcerative Colitis
P514 Beyond the First Attempt: A Multi-Centre UK Analysis of Second JAK Inhibitor Use in Ulcerative Colitis Open
Background Tofacitinib, filgotinib, and upadacitinib are Janus Kinase inhibitors (JAKi) effective in inducing and maintaining remission in moderate-to-severe ulcerative colitis (UC). Limited data exists regarding outcomes in patients on a …
View article: P821 Multi-site analysis of upadacitinib effectiveness in Crohn's Disease patients: A UK perspective
P821 Multi-site analysis of upadacitinib effectiveness in Crohn's Disease patients: A UK perspective Open
Background Upadacitinib, a selective Janus Kinase inhibitor, is the newest advanced therapy in our armamentarium for the treatment of Crohn’s Disease (CD). It has been licensed for use in moderate-to-severely active CD. However, we have li…
View article: JAK inhibitors for the treatment of inflammatory bowel disease: results of an international survey of perceptions, attitudes, and clinical practice
JAK inhibitors for the treatment of inflammatory bowel disease: results of an international survey of perceptions, attitudes, and clinical practice Open
Background Janus kinase inhibitors (JAKi) are small molecule drugs with demonstrated efficacy in inflammatory bowel disease (IBD). However, widespread utilisation may be hindered by safety concerns. Aims This is the first study assessing r…
View article: Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom
Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom Open
Background and Aims Despite intravenous (IV) vedolizumab being established for treatment of inflammatory bowel disease (IBD), the novel subcutaneous (SC) route of administration may provide numerous incentives to switch. However, large-sca…
View article: P268 Development and validation of a novel composite index for the assessment of endoscopic and histologic disease activity in pouchitis: The Atlantic pouchitis index.
P268 Development and validation of a novel composite index for the assessment of endoscopic and histologic disease activity in pouchitis: The Atlantic pouchitis index. Open
Background Several instruments have been used in clinical trials of pouchitis to define eligibility criteria and outcome measures but have not been formally validated. A need remains for a validated pouchitis instrument that is suitable fo…
View article: How achievable are STRIDE-II treatment targets in real-world practice and do they predict long-term treatment outcomes?
How achievable are STRIDE-II treatment targets in real-world practice and do they predict long-term treatment outcomes? Open
Objective The second iteration of the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) initiative recommends use of the Simple Endoscopic Score for Crohn’s disease (SES-CD) as a treatment target for patients with CD.…
View article: Development of a Core Outcome Set for Real-world Data in Inflammatory Bowel Disease: A European Crohn’s and Colitis Organisation [ECCO] Position Paper
Development of a Core Outcome Set for Real-world Data in Inflammatory Bowel Disease: A European Crohn’s and Colitis Organisation [ECCO] Position Paper Open
Background and Aims The utility of real-world data is dependent on the quality and homogeneity of reporting. We aimed to develop a core outcome set for real-world studies in adult patients with inflammatory bowel disease [IBD]. Methods Can…
View article: A retrospective cohort study: pre‐operative oral enteral nutritional optimisation for Crohnʼs disease in a <scp>UK</scp> tertiary <scp>IBD</scp> centre
A retrospective cohort study: pre‐operative oral enteral nutritional optimisation for Crohnʼs disease in a <span>UK</span> tertiary <span>IBD</span> centre Open
Summary Background Low‐quality evidence suggests that pre‐operative exclusive enteral nutrition (E/EN) can improve postoperative outcomes in patients with Crohn's disease (CD). It is not standard practice in most centres. Aims To test the …
View article: Thromboprophylaxis Use in Paediatric Inflammatory Bowel Disease: An International RAND Appropriateness Panel
Thromboprophylaxis Use in Paediatric Inflammatory Bowel Disease: An International RAND Appropriateness Panel Open
Background and Aims Thromboprophylaxis use in paediatric inflammatory bowel disease [IBD] is inconsistent. Current guidelines only support treating children with acute severe colitis with risk factors. We convened an international RAND pan…
View article: Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study
Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study Open
Objective Ustekinumab is an interleukin-12/interleukin-23 receptor antagonist licensed for the treatment of ulcerative colitis (UC). Clinical trial data were promising; however, real-world data are limited. We assessed the safety and effec…
View article: Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab
Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab Open
Background Sequential drug treatment with biological agents in ulcerative colitis (UC) is becoming increasingly complex. There are few studies comparing head-to-head outcomes in second-line treatments. The study assesses whether using anti…
View article: P453 Underutilisation of novel and alternative oral iron preparations may incur unnecessary cost in iron deficiency anaemia treatment in inflammatory bowel disease
P453 Underutilisation of novel and alternative oral iron preparations may incur unnecessary cost in iron deficiency anaemia treatment in inflammatory bowel disease Open
Background Iron deficiency anaemia (IDA) is a common extraintestinal manifestation of inflammatory bowel disease (IBD). Ferric salts are the cheapest preparations at approximately £2 per treatment course compared to more costly alternative…
View article: Depression, anxiety, and stress among inflammatory bowel disease patients during COVID‐19: A UK cohort study
Depression, anxiety, and stress among inflammatory bowel disease patients during COVID‐19: A UK cohort study Open
Background and Aim Patients with chronic diseases are believed to be at increased risk of mental health conditions during the COVID‐19 pandemic. We aimed to assess the incidence of psychological morbidity in inflammatory bowel disease (IBD…